Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
31 studies found for:    human epidermal growth factor receptor type 2 (HER2)
Show Display Options
Rank Status Study
1 Recruiting Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: trastuzumab;   Drug: chemotherapy
2 Completed A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
Conditions: Head and Neck Cancer;   Liver Cancer;   Breast Cancer;   Gastric Cancer;   Non-Small Cell Lung Cancer
Intervention: Drug: CUDC-101
3 Completed A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
Condition: Tumors
Intervention: Drug: CUDC-101
4 Active, not recruiting Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: CUDC-101;   Drug: Cisplatin;   Radiation: Radiation Therapy
5 Unknown  The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Condition: Solid Tumors
Intervention: Drug: Lapatinib and Sorafenib
6 Recruiting Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Conditions: Malignant Solid Tumour;   Breast Cancer;   Malignant Tumor of Colon;   GIST;   Ovarian Cancer
Intervention: Biological: HER-2 vaccine
7 Completed A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
Condition: Cancer
Intervention: Drug: ARRY-380, HER2 inhibitor; oral
8 Recruiting Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Conditions: Breast Neoplasms;   Breast Cancer;   Adenocarcinomas;   Metastatic Solid Tumors Characterized by HER2/Neu Expression
Intervention: Biological: Autologous Ad HER2 dendritic cell vaccine
9 Active, not recruiting Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
Condition: Neoplasms, Breast
Intervention: Drug: Lapatinib plus capecitabine
10 Recruiting Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Condition: HER-2 Positive Breast Cancer
Intervention: Drug: Pertuzumab, Trastuzumab and Eribulin
11 Recruiting Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Condition: Sarcoma
Interventions: Genetic: Autologous HER2-specific T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
12 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Biological: Pertuzumab;   Drug: Goserelin Acetate;   Procedure: Therapeutic Conventional Surgery;   Radiation: Whole Breast Irradiation;   Other: Laboratory Biomarker Analysis;   Drug: Aromatase Inhibition Therapy;   Other: Quality-of-Life Assessment
13 Completed A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)
Condition: Cancer
Interventions: Biological: V930;   Biological: V932
14 Withdrawn Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
Condition: Breast Cancer
Interventions: Drug: AMG 479;   Drug: Trastuzumab
15 Recruiting CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
Condition: Glioblastoma Multiforme (GBM)
Intervention: Genetic: Genetically modified HER.CAR CMV-specific CTLs
16 Recruiting Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: ado-trastuzumab emtansine;   Other: laboratory biomarker analysis;   Other: pharmacological study
17 Not yet recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
18 Recruiting Her 2 Testing in Indian Patients With Gastric Cancer
Condition: Gastric Cancer
Intervention:
19 Recruiting Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib;   Biological: Trastuzumab
20 Active, not recruiting Lauren Classifications and HER2 Status in Gastric Cancer Patients
Condition: Gastric Cancer
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Indicates status has not been verified in more than two years